Clinical Trials Browser

Phase 3 × Withdrawn × tislelizumab × Clear all

NCT05791097 2023-07-24

AdvanTIG-306

Phase 3 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT05564338 2023-06-07

Efficacy and Safety of Sitravatinib Plus Tislelizumab or Placebo Plus Tislelizumab Versus Placebo as Adjuvant Treatment in Participants With Hepatocellular Carcinoma

Phase 3 Withdrawn

Gastrointestinal

Carcinoma, Hepatocellular